Brooklyn Stock Financials


USD 0.54  0.02  3.85%   

Brooklyn Immunotherapeuti Revenue Per Employee is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Revenue Per Employee of 38,075.35 in 2021. Average Assets is likely to rise to about 42.4 M in 2022, whereas Net Income Per Employee is likely to drop (464.6 K) in 2022.
With this module, you can analyze Brooklyn financials for your investing period. You should be able to track the changes in Brooklyn Immunotherapeuti individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.

Brooklyn Most Recent Estimates

Diluted Eps
EPS Estimate Current Year
EPS Estimate Next Year
EPS Estimate Current Quarter
Earnings Share


19.16 Million

Understanding current and past Brooklyn Immunotherapeuti Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Brooklyn Immunotherapeuti's financial statements are interrelated, with each one affecting the others. For example, an increase in Brooklyn Immunotherapeuti's assets may result in an increase in income on the income statement.
The fundamental analysis of Brooklyn Immunotherapeuti is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Brooklyn Immunotherapeuti includes many different criteria found on its balance sheet. For example, investors should never minimize Brooklyn Immunotherapeuti's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Brooklyn Immunotherapeuti's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Brooklyn Immunotherapeuti.

Brooklyn Immunotherapeuti Cash

Chance Of Financial Distress
Less than 25
Brooklyn Immunotherapeutics has less than 25 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Brooklyn Immunotherapeuti stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Brooklyn Immunotherapeuti's official financial statements usually reflect Brooklyn Immunotherapeuti's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Brooklyn Immunotherapeuti. For example, before you start analyzing numbers published by Brooklyn accountants, it's critical to develop an understanding of what Brooklyn Immunotherapeuti's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Brooklyn Immunotherapeuti's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Brooklyn Immunotherapeuti's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Brooklyn Immunotherapeuti's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Brooklyn Immunotherapeutics. Please utilize our Beneish M Score to check the likelihood of Brooklyn Immunotherapeuti's management to manipulate its earnings.

Brooklyn Immunotherapeuti Company Summary

Brooklyn Immunotherapeuti competes with 3M. Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York. Brooklyn Immunotherapeuti operates under Biotechnology classification in the United States and is traded on NYSEMKT Exchange. It employs 10 people.
Healthcare, Biotechnology
InstrumentUSA Stock View All
ExchangeNYSEMKT Exchange
Older SymbolNTN
LocationNew York; U.S.A
Business Address10355 Science Center
Phone212 582 1199
Related EntityLCTX
CurrencyUSD - US Dollar
You should never invest in Brooklyn Immunotherapeuti without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Brooklyn Stock, because this is throwing your money away. Analyzing the key information contained in Brooklyn Immunotherapeuti's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Brooklyn Immunotherapeuti Key Financial Ratios

Generally speaking, Brooklyn Immunotherapeuti's financial ratios allow both analysts and investors to convert raw data from Brooklyn Immunotherapeuti's financial statements into concise, actionable information that can be used to evaluate the performance of Brooklyn Immunotherapeuti over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Brooklyn Immunotherapeuti reports annually and quarterly.

Brooklyn Immunotherapeuti Key Balance Sheet Accounts

201720182019202020212022 (projected)
Receivables780 K1.61 M317 K4 K4.6 K4.72 K
Accounts Payable938 K2.36 M2.43 M2.61 M2.35 M2.09 M
Total Assets16.57 M14.86 M14.12 M13.78 M32.43 M26.9 M
Current Assets9.64 M6.79 M6.07 M1.73 M18.77 M20.25 M
Assets Non Current6.93 M8.08 M8.05 M12.04 M13.66 M12.15 M
Cash and Equivalents3.38 M2.59 M3.26 M1.63 M16.98 M18.33 M
Total Debt5.41 M3.81 M6.08 M2.9 M2.72 M3.79 M
Debt Current5.24 M1.04 M3.17 M799 K426 K437.21 K
Debt Non Current172 K2.77 M2.91 M2.1 M2.3 M2.61 M
Deferred Revenue1.28 M3.63 M1.3 M462 K531.3 K545.28 K
Shareholders Equity5.54 M6.92 M5.09 M(11.58 M)6.5 M5.52 M
Total Liabilities11.03 M7.95 M9.03 M25.36 M25.93 M20.6 M
Current Liabilities10.75 M4.02 M6.09 M3.12 M3.68 M4.96 M
Tax Liabilities146 K120 K88 K134 K120.6 K171.92 K

Brooklyn Immunotherapeuti Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Brooklyn Immunotherapeuti's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201720182019202020212022 (projected)
Direct Expenses168 K302 K412 K385 K442.75 K541.54 K
Consolidated Income(1.08 M)(259 K)(2.05 M)(26.53 M)(122.31 M)(125.52 M)
Cost of Revenue7.71 M6.75 M8.07 M7.48 M8.61 M9.25 M
Gross Profit14.6 M14.52 M15.27 M12.32 M11.09 M12.18 M
Interest Expense576 K498 K389 K249 K286.35 K314.17 K
Net Income(1.08 M)(259 K)(2.05 M)(26.53 M)(122.31 M)(125.52 M)
Operating Expenses15.92 M15.06 M14.09 M7.21 M104.98 M113.27 M
Operating Income(1.4 M)203 K(1.77 M)(7.21 M)(104.98 M)(107.75 M)
Revenues22.31 M21.27 M23.34 M19.81 M17.83 M19.16 M
Income Tax Expense66 K(64 K)27 K5 K4.5 K4.62 K

Brooklyn Immunotherapeuti Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Brooklyn Immunotherapeuti. It measures of how well Brooklyn is doing because it can show the actual money that comes into and out of the company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Brooklyn Immunotherapeuti brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Brooklyn had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Brooklyn Immunotherapeuti has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201720182019202020212022 (projected)
Capital Expenditure(1.45 M)(1.58 M)(1.09 M)(39 K)(154 K)(166.16 K)
Depreciation Amortization and Accretion2.32 M2.76 M3.17 M98 K459 K471.08 K
Net Cash Flow or Change in Cash and Cash Equivalents(2.37 M)(592 K)623 K(3.47 M)15.36 M16.57 M
Issuance Repayment of Debt Securities(3.14 M)(1.62 M)(1.04 M)310 K(942 K)(966.79 K)
Net Cash Flow from Financing(1.47 M)(303 K)(1.1 M)4.67 M61.59 M66.45 M
Net Cash Flow from Investing(1.45 M)(1.58 M)(1.06 M)(39 K)(22.74 M)(23.34 M)
Net Cash Flow from Operations549 K1.36 M2.74 M(8.1 M)(23.49 M)(24.11 M)
Effect of Exchange Rate Changes on Cash24 K63 K(75 K)42 K48.3 K52.11 K
Share Based Compensation457 K443 K206 K91 K5.24 M5.65 M

Brooklyn Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Brooklyn Immunotherapeuti's current stock value. Our valuation model uses many indicators to compare Brooklyn Immunotherapeuti value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Brooklyn Immunotherapeuti competition to find correlations between indicators driving Brooklyn Immunotherapeuti's intrinsic value. More Info.
Brooklyn Immunotherapeutics is number one stock in return on equity category among related companies. It is number one stock in number of employees category among related companies . . Comparative valuation analysis is a catch-all model that can be used if you cannot value Brooklyn Immunotherapeuti by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Brooklyn Immunotherapeuti's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Brooklyn Immunotherapeuti's earnings, one of the primary drivers of an investment's value.

Brooklyn Immunotherapeuti Systematic Risk

Brooklyn Immunotherapeuti's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Brooklyn Immunotherapeuti volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was five with a total number of output elements of fifty-six. The Beta measures systematic risk based on how returns on Brooklyn Immunotherapeuti correlated with the market. If Beta is less than 0 Brooklyn Immunotherapeuti generally moves in the opposite direction as compared to the market. If Brooklyn Immunotherapeuti Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Brooklyn Immunotherapeuti is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Brooklyn Immunotherapeuti is generally in the same direction as the market. If Beta > 1 Brooklyn Immunotherapeuti moves generally in the same direction as, but more than the movement of the benchmark.

About Brooklyn Immunotherapeuti Financials

What exactly are Brooklyn Immunotherapeuti Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Brooklyn Immunotherapeuti's income statement, its balance sheet, and the statement of cash flows. Potential Brooklyn Immunotherapeuti investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Brooklyn Immunotherapeuti investors may use each financial statement separately, they are all related. The changes in Brooklyn Immunotherapeuti's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Brooklyn Immunotherapeuti's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines that you should keep in mind when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase year after year due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt to equity ratio because this number will tell you how much risk it has. If a company such as Brooklyn Immunotherapeuti is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to try and figure out if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that net revenue of Brooklyn grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only grown by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Brooklyn Immunotherapeuti Thematic Clasifications

Brooklyn Immunotherapeutics is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
Pharmaceutical Products Idea
Pharmaceutical ProductsView
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas

Brooklyn Immunotherapeuti July 2, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Brooklyn Immunotherapeuti help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Brooklyn Immunotherapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Brooklyn Immunotherapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Brooklyn Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Brooklyn Immunotherapeuti's daily price indicators and compare them against related drivers.
Information Ratio(0.29)
Maximum Drawdown30.36
Value At Risk(10.71)
Potential Upside8.33
Continue to Trending Equities. Note that the Brooklyn Immunotherapeuti information on this page should be used as a complementary analysis to other Brooklyn Immunotherapeuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Brooklyn Stock analysis

When running Brooklyn Immunotherapeuti price analysis, check to measure Brooklyn Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brooklyn Immunotherapeuti is operating at the current time. Most of Brooklyn Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of Brooklyn Immunotherapeuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brooklyn Immunotherapeuti's price. Additionally, you may evaluate how the addition of Brooklyn Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Money Managers
Screen money managers from public funds and ETFs managed around the world
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Transaction History
View history of all your transactions and understand their impact on performance
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Is Brooklyn Immunotherapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brooklyn Immunotherapeuti. If investors know Brooklyn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brooklyn Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
29.7 M
Return On Assets
Return On Equity
The market value of Brooklyn Immunotherapeuti is measured differently than its book value, which is the value of Brooklyn that is recorded on the company's balance sheet. Investors also form their own opinion of Brooklyn Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Brooklyn Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brooklyn Immunotherapeuti's market value can be influenced by many factors that don't directly affect Brooklyn Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brooklyn Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Brooklyn Immunotherapeuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brooklyn Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.